[1]
T. Sogulasvhili, N. Gamkrelidze, N. Pavliashvili, L. Kvatchadze, and M. Katsadze, “Colchicine Plus Rosuvastatin/Ezetimibe for Residual Cardiovascular Risk: Mechanistic Rationale, Safety Concerns and Research Priorities”, GBMN, vol. 4, no. 3, pp. 177–186, Jul. 2026, doi: 10.52340/GBMN.2026.01.01.180.